Drug intelligence / Profile preview

insulin lispro mix25

Development stage
Approved
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Insulin lispro mix25 is a premixed combination of two human insulin analogs used to control blood glucose in people with diabetes mellitus. It contains 25% rapid-acting insulin lispro and 75% intermediate-acting insulin lispro protamine. The rapid-acting component allows for quick onset of action, while the protamine-bound form provides prolonged activity. Insulin lowers blood glucose by stimulating peripheral glucose uptake (mainly in muscle and fat) and inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis while enhancing protein synthesis. Insulin lispro mix25 is administered subcutaneously within 15 minutes before a meal to manage both type 1 and type 2 diabetes[1][3][5][7].

Brand names
Humalog Mix25
Other names
insulin lispro mix25insulin lispro protamine and insulin lispro injectable suspension mix25Humalog Mix 25
02

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro mix25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro mix25.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call